Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder of the central nervous system. Current approaches for AD treatment only ameliorate symptoms. Therapeutic strategies that target the pathological processes of the disease remain elusive. Fluoxetine (FLX) is one of the most widely used antidepressants for the treatment of depression and anxiety associated with AD, however, it is unknown if the drug affects the pathogenesis of the disease. We showed that FLX improved spatial memory, learning and emotional behaviors of APP/PS1 mice, a well characterized model of AD. In the same mice, FLX effectively prevented the protein loss of synaptophysin (SYP) and microtubuleassociated protein 2 (MAP2). FLX was unable to prevent plaque formation, but significantly lowered high levels of soluble β-amyloid (Aβ) in brain tissue, cerebrospinal fluid (CSF) and blood sera. FLX also effectively inhibited the phosphorylation of amyloid precursor protein (APP) at T668, which may be a possible mechanism of the reduced Aβ production in APP/PS1 mouse after treatment.
Keywords: Amyloid precursor protein (APP), Alzheimer’s disease (AD), behavior, fluoxetine, soluble Aβ.
Current Alzheimer Research
Title:Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble β-Amyloid in APP/PS1 Mice
Volume: 11 Issue: 7
Author(s): Junhui Wang, Yanbo Zhang, Haiyun Xu, Shenghua Zhu, Hongxing Wang, Jue He, Handi Zhang, Huining Guo, Jiming Kong, Qingjun Huang and Xin-Min Li
Affiliation:
Keywords: Amyloid precursor protein (APP), Alzheimer’s disease (AD), behavior, fluoxetine, soluble Aβ.
Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disorder of the central nervous system. Current approaches for AD treatment only ameliorate symptoms. Therapeutic strategies that target the pathological processes of the disease remain elusive. Fluoxetine (FLX) is one of the most widely used antidepressants for the treatment of depression and anxiety associated with AD, however, it is unknown if the drug affects the pathogenesis of the disease. We showed that FLX improved spatial memory, learning and emotional behaviors of APP/PS1 mice, a well characterized model of AD. In the same mice, FLX effectively prevented the protein loss of synaptophysin (SYP) and microtubuleassociated protein 2 (MAP2). FLX was unable to prevent plaque formation, but significantly lowered high levels of soluble β-amyloid (Aβ) in brain tissue, cerebrospinal fluid (CSF) and blood sera. FLX also effectively inhibited the phosphorylation of amyloid precursor protein (APP) at T668, which may be a possible mechanism of the reduced Aβ production in APP/PS1 mouse after treatment.
Export Options
About this article
Cite this article as:
Wang Junhui, Zhang Yanbo, Xu Haiyun, Zhu Shenghua, Wang Hongxing, He Jue, Zhang Handi, Guo Huining, Kong Jiming, Huang Qingjun and Li Xin-Min, Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble β-Amyloid in APP/PS1 Mice, Current Alzheimer Research 2014; 11 (7) . https://dx.doi.org/10.2174/1567205011666140812114715
DOI https://dx.doi.org/10.2174/1567205011666140812114715 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience CGRP Receptor Antagonism and Migraine Therapy
Current Protein & Peptide Science Recent Advancements in Anti-Migraine Drug Research: Focus on Attempts to Decrease Neuronal Hyperexcitability
Recent Patents on CNS Drug Discovery (Discontinued) Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Increasing Access to HIV Testing for Women by Simplifying Pre- and Post-Test Counseling
Current Women`s Health Reviews Alzheimers Disease: SPECT and PET Tracers for Beta-Amyloid Imaging
Current Alzheimer Research The Contribution of Host Genetics to TB Disease
Current Respiratory Medicine Reviews Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Drug Targeting Systems for Cancer Therapy: Nanotechnological Approach
Mini-Reviews in Medicinal Chemistry Possibility that the Onset of Autism Spectrum Disorder is Induced by Failure of the Glutamine-Glutamate Cycle
Current Molecular Pharmacology Syphilis: An Epidemiological Review
Current Women`s Health Reviews Methoxychalcones: Effect of Methoxyl Group on the Antifungal, Antibacterial and Antiproliferative Activities
Medicinal Chemistry Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Current Drug Metabolism Host-Cell Survival and Death During Chlamydia Infection
Current Immunology Reviews (Discontinued) HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research Conformational Flexibility in Designing Peptides for Immunology: The Molecular Dynamics Approach
Current Computer-Aided Drug Design